Stock GTBP GT BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Market Closed - Nasdaq
Other stock markets
 21:00:00 17/05/2024 BST 		5-day change 1st Jan Change
3.12 USD -4.59% Intraday chart for GT Biopharma, Inc. -6.17% -59.22%
03-26 GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
02-01 GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall MT

Evolution of the average Target Price on GT Biopharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

92523cfadc79.CxpseDY7VDsmuRljYuWyrQzHhKsK3v69SeWLab9tLEM.Unw9N1pDImxP_V8GOpLE-F-Essp6q5LNDaq8Lu9Ucw8mdjkxG3YzdXfzIQ~850e4875494e831244911f6b81362b5c

Analyst Recommendations on GT Biopharma, Inc.

EF Hutton Starts GT Biopharma at Hold With $2 Price Target MT
HC Wainwright Adjusts Price Target on GT Biopharma to $5 From $25, Reiterates Buy Rating MT
Roth Capital Cuts GT Biopharma to Neutral From Buy, Price Target to $3 From $9 MT
B. Riley Lowers GT Biopharma's Price Target to $18 from $26 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
GT BIOPHARMA : B. Riley Raises GT Biopharma's PT to $26 from $21, Notes Steady Progress of Dose-Escalation Trial of Lead Asset GTB-3550; Keeps Buy Rating MT
GT BIOPHARMA : HC Wainwright Starts GT Biopharma at Buy With $25 Price Target MT
GT BIOPHARMA : B. Riley Starts GT Biopharma at Buy with $21 PT, Says Solid Tumor Indications Represent Source of Potential Upside MT
GT BIOPHARMA : Roth Capital Starts GT Biopharma at Buy With $25 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.12 USD
Average target price
150 USD
Spread / Average Target
+4,707.70%
High Price Target
150 USD
Spread / Highest target
+4,707.70%
Low Price Target
150 USD
Spread / Lowest Target
+4,707.70%

Consensus detail

Consensus revision (last 18 months)

Analysts covering GT Biopharma, Inc.

EF Hutton
HC Wainwright
Roth Capital Partners
B. Riley

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GTBP Stock
  4. Consensus GT Biopharma, Inc.